Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
Siemens Healthineers agreed to acquire Novartis AG's (NYSE:NVS) diagnostics arm for $223.5 million (200 million euros) in a deal meant to enhance its cancer treatments.
西门子医疗同意收购诺华制药（纽交所:NVS）的诊断部门，以提升其癌症治疗业务。
Both companies confirmed the acquisition, and it involved Advanced Accelerator Applications, a division Novartis purchased in 2017.
两家公司均确认了收购交易，其中涉及2017年诺华制药收购的Advanced Accelerator Applications部门。
The Financial Times reported that Advanced Accelerator Applications operates Europe's second-largest network of cyclotrons. The unit produces radioactive compounds essential for positron emission tomography (PET) scans that detect cancer and other diseases.
《金融时报》报道称，Advanced Accelerator Applications运营着欧洲第二大环形加速器网络。该部门生产对于正电子发射计算机断层扫描（PET）诊断癌症和其他疾病至关重要的放射性化合物。
Also Read: Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug.
另请参阅：法官裁定不支持诺华制药阻止其热卖心脏病药物的仿制品推出。
The deal will expand Siemens Healthineers' PET radiopharmaceuticals business—the world's largest—into Europe, strengthening its leading position in the imaging market, the Financial Times report adds.
这笔交易将扩大西门子医疗业务的PET放射性药物业务——世界上最大的业务——进入欧洲，加强了其在成像市场的领先地位，据《金融时报》报道。
PET scans, often used for diagnosing cancers like lung, breast, and cervical cancer, have become increasingly vital, especially in monitoring cancer spread and treatment response. While PET imaging is more costly and limited in European state-run healthcare systems compared to other techniques like MRI, it is now considered a standard diagnostic tool for certain cancer types.
PET扫描通常用于诊断肺癌、乳腺癌和子宫颈癌等癌症，尤其在监测癌症扩散和治疗反应方面变得越来越重要。尽管与MRI等其他技术相比，PET成像在欧行政医疗系统中成本更高且受限，但现在被视为某些癌症类型的标准诊断工具。
Erlangen, Germany-based Siemens Healthineers, spun off from Siemens in 2017, sees the acquisition as strategically critical. The radioactive compounds used in PET scans have a short half-life and must be administered on the day they are produced, necessitating localized production close to patients.
总部位于德国爱尔朗根的西门子医疗业务于2017年从西门子集团分拆，将收购视为战略上的关键性。用于PET扫描的放射性化合物半衰期短，并且必须在生产当天进行注射，因此需要在患者附近进行局部生产。
Siemens Healthineers' imaging division remains the company's largest revenue generator, contributing nearly 3 billion euros in sales in the last quarter, accounting for over half of total group revenues.
西门子医疗业务的成像部门仍然是公司最大的营业收入来源，上个季度实现接近30亿欧元的销售额，占总集团营业收入的一半以上。
Novartis decided to sell Advanced Accelerator Applications' diagnostics unit, viewing it as a low-growth segment.
诺华制药决定卖出爱文思控股的诊断部门，认为这是一个增长较慢的领域。
The pharma giant acquired Advanced Accelerator Applications for $3.9 billion to gain access to its innovative radiopharma drugs, including Lutathera, a treatment for neuroendocrine tumors expected to generate $704 million in sales this year.
这家制药巨头以39亿美元收购爱文思控股，以获得其创新性放射性药物，包括用于神经内分泌肿瘤治疗的Lutathera，今年预计将带来7.04亿美元的销售额。
Novartis noted that a dedicated diagnostics owner would better support molecular imaging's growth prospects, leading to this divestiture.
诺华制药指出，一个专门的诊断部门所有者将更好地支持分子影像学的增长前景，从而导致这一出售。
In addition to the sale, Novartis and Siemens Healthineers will collaborate to enhance the supply of nuclear isotopes used in radiopharma drugs like Lutathera.
除了销售之外，诺华制药和西门子医疗将合作增强用于像Lutathera这样的放射性药物中使用的核同位素的供应。
Price Action: NVS stock is up 0.47% at $119.12 during the premarket session at last check Monday.
股价走势：在上一个周一最后一次检查时，诺华制药(NVS)股价在盘前交易中上涨0.47%，报119.12美元。
- Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer.
- 来自默沙东、百杰康和百济神州的癌症药物受到质疑，因为FDA委员会将讨论限制PD-1药物用于胃癌治疗。
